Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Mantle-Cell 5Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, B-Cell 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Burkitt Lymphoma 1Advanced Haematological Malignancies 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × acalabrutinib × Clear all
NCT02537444 2019-09-25

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Acerta Pharma BV

Phase 2 Completed
78 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡